Die Inzidenz eines Mammakarzinoms während der Schwangerschaft oder bis zu einem Jahr post partum ist gering. Hormonelle Einflüsse spielen eine wesentliche Rolle in der Karzinogenese des Mammakarzinoms, dennoch scheint die Prognose für Frauen in und außerhalb der Schwangerschaft identisch zu sein. Die Diagnose ist aufgrund vielfältiger Veränderungen der Brustdrüse intra graviditatem deutlich erschwert. Die sehr häufig verspätete Diagnosestellung erklärt zu einem gewissen Teil die schlechten Überlebensdaten. Die Therapie darf sich nicht nur an den möglichen Nebenwirkungen für die Mutter ausrichten, sondern muss ebenso die Kurz- und Langzeittoxizität für das ungeborene Leben berücksichtigen. Die operative Therapie folgt den bekannten Empfehlungen. Die adjuvante Bestrahlung sollte nach der Geburt erfolgen. Eine (neo-)adjuvante, anthrazyklinhaltige Chemotherapie scheint im zweiten und dritten Trimenon für Mutter und Kind ohne wesentliche Nebenwirkungen möglich zu sein. Die angewandten Therapien können einen negativen Einfluss auf die Fertilität der jungen Frauen haben. Eine Schwangerschaft nach einem behandelten Mammakarzinom verändert die Prognose der Patientinnen nicht.
Abstract
Breast cancer during pregnancy or the first year postpartum is rare. While hormonal factors play an important role in the carcinogenesis of breast cancer, the prognosis of pregnant patients appears to be identical to that of nonpregnant women. The physiologic changes the breast undergoes with pregnancy can make it difficult to diagnose cancer and delayed diagnosis may contribute to unfavorable survival. Treatment plans need to consider potential immediate and long-term toxicity for the fetus. Surgical treatment should be the same as for nonpregnant women. Adjuvant radiation should be deferred until after delivery. Neoadjuvant anthracycline-based chemotherapy in the second and third trimester appears to be without significant side effects for mother or fetus. Certain treatment modalities can impair future fertility. Pregnancy after breast cancer does not affect the prognosis.
Literatur
1
Gemignani M L, Petrek J A, Borgen P I.
Breast cancer and pregnancy.
Surg Clin North Am.
1999;
79
1157-1169
2
Smith L H, Dalrymple J L, Leiserowitz G S. et al .
Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997.
Am J Obstet Gynecol.
2001;
184
1504-1512
5
Helewa M, Levesque P, Provencher D, Lea R H, Rosolowich V, Shapiro H M.
Breast cancer, pregnancy, and breastfeeding.
J Obstet Gynaecol Can.
2002;
24
164-180
9
Harrington S W.
Carcinoma of the breast: results of surgical treatment when the carcinoma occurred in the course of pregnancy or lactation and when pregnancy occurred subsequent to operation, 1910 - 1933.
Ann Surg.
1937;
106
690
17
Bonnier P, Romain S, Dilhuydy J M. et al .
Influence of pregnancy on the outcome of breast cancer: a case control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group.
Int J Cancer.
1997;
72
720-727
19
Ishida T, Yokoe T, Kasumi F. et al .
Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: Analysis of case control study in Japan.
J Cancer Res.
1992;
83
1143-1149
21
Elledge R M, Ciocca D R, Langone G, McGuire W L.
Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 1993; 71: 2499 - 2506.
Comment in: Cancer.
1993;
72
2291-2292
30 Wagner L K, Lester R G, Saldana L. Exposure of the Pregnant Patient to Diagnostic Radiation: A Guide to Medical Management. - The Amount of Radiation Absorbed by the Conceptus. Philadelphia; JB Lipincott 1985: 40
31
Sabel M, Aichinger U, Schulz-Wendlandt R.
Radiation exposure in x-ray mammography.
Rofo Fortschr geb Rontgenstr Neue Bildgeb Verfahr.
2001;
173
79-91
32
Kal H B, Struikmans H.
Pregnancy and medical irridiation: summary and conclusions from the International Commission on Radiological Protection, Publication 84.
Ned Tijdschr Geneeskd.
2002;
146
299
33
Kuerer H M, Gwyn K, Ames F C, Theriault R L.
Conservative surgery and chemotherapy for breast carcinoma during pregnancy.
Surgery.
2002;
131
108-110
34
Schwartz G F, Giuliano A E, Veronesi U. Consensus Conference Committee .
Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19 - 22, 2001, Philadelphia, Pennsylvania.
Cancer.
2002;
94
2542-2551
41
Giannakopoulou C, Manoura A, Hatzidaki E. et al .
Multimodal cancer chemotherapy during the first and second trimester of pregnancy.
Eur J Obstet Gynecol Repord Biol.
2000;
91
95-97
44
Berry D L, Theriault R L, Holmes F A. et al .
Management of breast cancer during pregnancy using a standardized protocol.
J Clin Oncol.
1999;
17
855-861
45
De Santis M, Lucchese A, De Carolis S, Ferrazani S, Caruso A.
Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel.
Eur J Cancer Care.
2000;
9
235-237
47
Isaacs R J, Hunter W, Clark K.
Tamoxifen as systemic treatment of advanced breast cancer during pregnancy - case report and literature review.
Gynecol Oncol.
2001;
80
405-408
48
Halakivi-Clarke L, Cho E, Onojafe I, Liao D J, Clarke R.
Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring.
Clin Cancer Res.
2000;
6
305-308
50
Cobleigh M A, Bines J, Harris J, Lofolette S S. et al .
Amenorrhoea following adjuvant chemotherapy for breast cancer.
Proc Am Soc Clin Oncol.
1995;
14
(Abstract 158)
54
Jordan V C, Fritz N F, Langan-Fahey S. et al .
Alteration of endocrine parameters in premenopausal women with breast cancer during long term adjuvant therapy with tamoxifen as the single agent.
J Natl Cancer Inst.
1992;
83
1488
59
Sankila R, Heinavaara S, Hakulinen T.
Survival of breast cancer patients after subsequent term pregnancy: “Healthy mother effect”.
Am J Obstet Gynecol.
1994;
170
818-823
60
von Schoultz E, Johansson H, Wilking N. et al .
Influence of prior and subsequent pregnancy on breast cancer prognosis.
J Clin Oncol.
1995;
13
430-434
62
Gelber S, Coates A S, Goldhrisch A. et al .
Effect of pregancy on overall survival after the diagnosis of early-stage breast cancer.
J Clin Oncol.
2001;
19
1671-1675
63
Harvey J C, Rosen P P, Ashikari R. et al .
The effect of pregnancy on the prognosis of carcinoma of the breast following radical mastectomy.
Surg Gynecol Obstet.
1981;
153
723-725
68
Dow K H, Harris J R, Roy C.
Pregnancy after breast-conserving surgery and radiation therapy for breast cancer.
J Natl Cancer Inst Monogra.
1994;
16
131-137
73
Jakesz R, Hausmaninger H, Samonigg H.
Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer.
Eur J Cancer.
2002;
38
327-332
75
Poikonen P, Saarto T, Elomaa A. et al .
Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients.
Eur J Cancer.
2000;
36
43-48
76
Del Mastro L, Venturini M, Sertoli M R.
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications.
Breast Cancer Res Treat.
1997;
43
183-190
77
Aziz S, Pervez S, Khan S. et al .
Case control study of novel prognostic markers and disease outcome in pregnancy/lactation associated breast carcinoma.
Pathol Res Prac.
2003 (in press);
80
Lehner R, Strohmer H, Jirecek S, Goharkhay N, Tringler B, Barrada M.
Placental insufficiency and maternal death caused by advanced stage of breast cancer in third trimester.
Eur J Obstet Gynecol Reprod Biol.
2001;
99
272-273
81
Keleher A J, Theriault R L, Gwyn K M, Hunt K K, Stelling C B, Singletary S E, Ames F C, Buchholz T A, Sahin A A, Kuerer H M.
Multidisciplinary management of breast cancer concurrent with pregnancy.
J Am Coll Surg.
2002;
194
54-64
82
Tewari K, Cappuccini F, Gambino A, Kohler M F, Pecorelli S, DiSaia P J.
Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy: a report of two cases and review of issues specific to the management of cervical carcinoma in pregnancy including planned delay of therapy.
Cancer.
1998;
82
1529-1534
83
Ballast A, Hellmeyer L, Emons G, Ramaswamy A, Förster B, Schmidt S.
Chemotherapie mit Adriamycin und Cyclophosphamid beim Mammakarzinom in der Schwangerschaft: Ein Fallbericht.
Geburtsh Frauenheilk.
1999;
59
531-534
85
Fornier M N, Modi S, Hudis C A.
Incidence of amenorrhea (A) in breast cancer (BC) patients (pts) ≤ 40 years of age after paclitaxel (T)-based adjuvant chemotherapy (CT).
Breast Cancer Res Treat.
2002;
Abstr. 645